Gaucher Disease, Type 1

Also known as: Type I Gaucher Disease / Gaucher Disease, Type I / Gaucher Disease Type I / Type 1 Gaucher Disease / Gaucher Disease Type 1 / Gaucher's disease type I / Type 1 Gaucher's disease / Chronic non-neuropathic Gaucher's disease (disorder)

DrugDrug NameDrug Description
DB09039EliglustatA glucosylceramide synthase used to treat type 1 Gaucher disease in patients who are CYP2D6 extensive, intermediate, or poor metabolizers, based on the FDA-approved test.
DB00053ImigluceraseA form of recombinant human beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease.
DB08876Taliglucerase alfaA hydrolytic lysosomal glucocerebroside specific enzyme, used for long term enzyme replacement therapy in patients with Type 1 Gaucher disease.
DB06720Velaglucerase alfaAn enzyme replacement therapy used for the long-term treatment of for pediatric and adult patients with type 1 Gaucher disease.
DrugDrug NamePhaseStatusCount
DB06742Ambroxol1 / 2Suspended1
DB06151Acetylcysteine2Suspended1
DB04545Afegostat2Completed3
DB06742Ambroxol2Recruiting1
DB05025Arimoclomol2Active Not Recruiting1
DB05715Eliglustat2Completed1
DB09039Eliglustat2Completed1
DB00053Imiglucerase2Active Not Recruiting1
DB14966Venglustat2Active Not Recruiting1
DB05715Eliglustat3Completed2
DB09039Eliglustat3Completed2
DB09039Eliglustat3Recruiting1
DB00053Imiglucerase3Completed3
DB00053Imiglucerase3Recruiting1
DB00419Miglustat3Completed1
DB05543Velaglucerase alfa3Completed3
DB06720Velaglucerase alfa3Completed3
DB00053Imiglucerase4Completed2
DB08876Taliglucerase alfa4Withdrawn1
DB06720Velaglucerase alfa4Active Not Recruiting1
DB06720Velaglucerase alfa4Withdrawn1
DB08876Taliglucerase alfaNot AvailableActive Not Recruiting1
DB05543Velaglucerase alfaNot AvailableApproved for Marketing1
DB06720Velaglucerase alfaNot AvailableApproved for Marketing1